Picture loading failed.

Anti-TNFA therapeutic antibody (Pre-made Certolizumab biosimilar,Fab) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Certolizumab pegol, sold under the brand name Cimzia, is a biologic medication for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-100-1mg 1mg 3090
GMP-Bios-ab-100-10mg 10mg 21890
GMP-Bios-ab-100-100mg 100mg 148000
GMP-Bios-ab-100-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-TNFA therapeutic antibody (Pre-made Certolizumab biosimilar,Fab)
INN Name Certolizumab
TargetTNFA
FormatFab
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure5wuv:HL/5wux:HL:AB:CD
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2004
Year Recommended2004
CompaniesUCB
Conditions ApprovedAnkylosing spondylitis;Crohn's disease;Plaque psoriasis;Psoriatic arthritis;Rheumatoid arthritis;Spondylitis;Non-radiographic axial spondyloarthritis
Conditions ActiveInterstitial cystitis;Juvenile rheumatoid arthritis
Conditions DiscontinuedCognition disorders
Development Techna